Given the many shared biological pathways of different oncogenic drivers, we speculate that a PRMT1-targeting strategy might have broader application in combination with other targeted therapies and in other cancer types (e.g., ALK-driven lung cancer, KRASmut colorectal cancer, or HER2-driven breast cancer). This evidence concerns the gene ERBB2 and breast cancer.